| Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More | Ben Fidler | 09/13/19 | National |
| Bio Leaders Mourn Passing of Genzyme Exec, Orphan Drug Innovator Termeer | Ben Fidler | 05/14/17 | Boston |
| East Coast Biotech Roundup: NY Disruptors, Commense, Regeneron, & More | Ben Fidler | 04/01/16 | Boston |
| East Coast Biotech Roundup: WaVe, Shkreli, Intarcia & More | Ben Fidler | 08/21/15 | Boston |
| Aveo, Still Breathing, Cuts New Deal With Novartis | Ben Fidler | 08/17/15 | Boston |
| East Coast Biotech Roundup: PrecisionFDA, Avitide, Foresight & More | Ben Fidler | 08/07/15 | Boston |
| Fresh Off Boston Move, CoLucid Plots IPO For Migraine Drug Push | Frank Vinluan | 03/31/15 | Raleigh Durham |
| East Coast Biotech Roundup: Regeneron, Sage, Tara, Alnylam, & More | Ben Fidler | 11/14/14 | Boston |
| East Coast Biotech Roundup: Proteon, Ataxion, NY Genome/Watson, & More | Ben Fidler | 03/21/14 | Boston |
| East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More | Ben Fidler | 01/31/14 | Boston |
| Biotech and Fantasy Football Picks for Fall 2013 | Luke Timmerman | 09/03/13 | National |
| East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More | Ben Fidler | 07/26/13 | Boston |
| SEC Comes Calling For Aveo As FDA Panel Fallout Continues | Ben Fidler | 07/11/13 | Boston |
| East Coast Life Sciences Roundup: Agios, Ludwig/CRI, Celgene | Ben Fidler | 06/14/13 | Boston |
| FDA Declines To Approve Aveo’s Drug For Kidney Cancer | Ben Fidler | 06/10/13 | Boston |
| East Coast Life Sciences Roundup: ASCO, Follica, Aveo, & More | Ben Fidler | 06/07/13 | Boston |
| Aveo Rests Fate on Remaining Mid-Stage Trials For Cancer Drug | Ben Fidler | 06/05/13 | Boston |
| Aveo Cuts 140 Jobs As Fallout From FDA Panel Continues | Ben Fidler | 06/04/13 | Boston |
| Astellas Tells Aveo to Go It Alone in Kidney Cancer | Ben Fidler | 05/24/13 | Boston |
| Henri Termeer on Startups, Drug Prices, Getting Older (Part 1) | Luke Timmerman | 05/13/13 | National |
| East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More | Ben Fidler | 05/10/13 | Boston |
| Lessons For Drug Development From The Aveo Buzzsaw | Luke Timmerman | 05/06/13 | National |
| Aveo Shares Fall as FDA Questions Cancer Drug Survival Trend | Luke Timmerman | 08/02/12 | Boston |
| ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines | Luke Timmerman | 06/05/12 | National |
| Why Would a Biotech Company Go the Trouble of Changing Its Name? | Luke Timmerman | 06/04/12 | National |
